Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Jul 15;17(14):3510.
doi: 10.3390/ma17143510.

Novel Collagen Membrane Formulations with Irinotecan or Minocycline for Potential Application in Brain Cancer

Andreea-Anamaria Idu  1   2 , Mădălina Georgiana Albu Kaya  3 , Ileana Rău  1 , Nicoleta Radu  4   5 , Cristina-Elena Dinu-Pîrvu  6   7 , Mihaela Violeta Ghica  6   7
Affiliations

Novel Collagen Membrane Formulations with Irinotecan or Minocycline for Potential Application in Brain Cancer

Andreea-Anamaria Idu et al. Materials (Basel). .

Abstract

Our study explores the development of collagen membranes with integrated minocycline or irinotecan, targeting applications in tissue engineering and drug delivery systems. Type I collagen, extracted from bovine skin using advanced fibril-forming technology, was crosslinked with glutaraldehyde to create membranes. These membranes incorporated minocycline, an antibiotic, or irinotecan, a chemotherapeutic agent, in various concentrations. The membranes, varying in drug concentration, were studied by water absorption and enzymatic degradation tests, demonstrating a degree of permeability. We emphasize the advantages of local drug delivery for treating high-grade gliomas, highlighting the targeted approach's efficacy in reducing systemic adverse effects and enhancing drug bioavailability at the tumor site. The utilization of collagen membranes is proposed as a viable method for local drug delivery. Irinotecan's mechanism, a topoisomerase I inhibitor, and minocycline's broad antibacterial spectrum and inhibition of glial cell-induced membrane degradation are discussed. We critically examine the challenges posed by the systemic administration of chemotherapeutic agents, mainly due to the blood-brain barrier's restrictive nature, advocating for local delivery methods as a more effective alternative for glioblastoma treatment. These local delivery strategies, including collagen membranes, are posited as significant advancements in enhancing therapeutic outcomes for glioblastoma patients.

Keywords: bioengineering; collagen-based membranes; glioblastoma; irinotecan; minocycline; nanotechnology.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest.

Figures

Figure 6
Figure 6
Antibacterial effects of minocycline. (a) Test performed on thin biofilm; (b) minimal inhibitory concentration of minocycline on S. aureus, for different applied standards (data adapted after Bidell et al., 2021 [44]); (c) effect of minocycline 5 mg/mL on E. coli; (d) effect of thin film M1 on E. coli; (e) effect of minocycline 5 mg/mL on S. aureus; (f) effect of thin film M1 on S. aureus; (g) effect of thin film IR4 with irinotecan on E. coli; (h) effect of thin film IR3 with irinotecan on E. coli; (i) effect of thin film IR1 with irinotecan on E. coli. n.d. = not determined; CLSI = Clinical and Laboratory Standard Institute; EUCAST = European Committee on Antimicrobial Susceptibility; FDA = Food and Drug Administration, USA.
Figure 1
Figure 1
Collagen membranes with minocycline 40% (a) and irinotecan 10% (b).
Figure 2
Figure 2
Water absorption for collagen membranes with different concentrations of minocycline. A p-value > 0.5 indicates that the results obtained are not statistically significant. “*” corresponds to results with statistical significance (0.5 < p < 0.1), “**” corresponds to distinctly statistically significant results (0.1 ≤ p < 0.01), and “***” corresponds to highly statistically significant results (p ≤ 0.01).
Figure 3
Figure 3
Water absorption for the collagen-based membranes with different irinotecan concentrations. A p-value > 0.5 indicates that the results obtained are not statistically significant. “*” corresponds to results with statistical significance (0.5 < p < 0.1), “**” corresponds to distinctly statistically significant results (0.1 ≤ p < 0.01), and “***” corresponds to highly statistically significant results (p ≤ 0.01).
Figure 4
Figure 4
Collagenase degradation of collagen membranes with minocycline. A p-value > 0.5 indicates that the results obtained are not statistically significant. “*” corresponds to results with statistical significance (0.5 < p < 0.1), “**” corresponds to distinctly statistically significant results (0.1 ≤ p < 0.01), and “***” corresponds to highly statistically significant results (p ≤ 0.01).
Figure 5
Figure 5
Collagenase degradation of the collagen membranes with irinotecan. A p-value > 0.5 indicates that the results obtained are not statistically significant. “*” corresponds to results with statistical significance (0.5 < p < 0.1), “**” corresponds to distinctly statistically significant results (0.1 ≤ p < 0.01), and “***” corresponds to highly statistically significant results (p ≤ 0.01).
Figure 7
Figure 7
Time-dependent cumulative release patterns of minocycline from collagen membranes.
Figure 8
Figure 8
Time-dependent cumulative release patterns of irinotecan from collagen membranes.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Louis D.N., Perry A., Reifenberger G., von Deimling A., Figarella-Branger D., Cavenee W.K., Ohgaki H., Wiestler O.D., Kleihues P., Ellison D.W. The 2016 World Health Organization Classification of Tumors of the Central Nervous System: A summary. Acta Neuropathol. 2016;131:803–820. doi: 10.1007/s00401-016-1545-1. - DOI - PubMed
    1. Weller M., van den Bent M., Hopkins K., Tonn J.C., Stupp R., Falini A., Cohen-Jonathan-Moyal E., Frappaz D., Henriksson R., Balana C., et al. EANO guideline for the diagnosis and treatment of anaplastic gliomas and glioblastoma. Lancet Oncol. 2014;15:e395–e403. doi: 10.1016/S1470-2045(14)70011-7. - DOI - PubMed
    1. Weller M., van den Bent M., Tonn J.C., Stupp R., Preusser M., Cohen-Jonathan-Moyal E., Henriksson R., Le Rhun E., Balana C., Chinot O., et al. European Association for Neuro-Oncology (EANO) guideline on the diagnosis and treatment of adult astrocytic and oligodendroglial gliomas. Lancet Oncol. 2017;18:e315–e329. doi: 10.1016/S1470-2045(17)30194-8. - DOI - PubMed
    1. Soffietti R., Baumert B.G., Bello L., Von Deimling A., Duffau H., Frénay M., Grisold W., Grant R., Graus F., Hoang-Xuan K., et al. Guidelines on management of low-grade gliomas: Report of an EFNS-EANO Task Force. Eur. J. Neurol. 2010;17:1124–1133. doi: 10.1111/j.1468-1331.2010.03151.x. - DOI - PubMed
    1. Wen P.Y., Macdonald D.R., Reardon D.A., Cloughesy T.F., Sorensen A.G., Galanis E., Degroot J., Wick W., Gilbert M.R., Lassman A.B., et al. Updated response assessment criteria for high-grade gliomas: Response assessment in neuro-oncology working group. J. Clin. Oncol. 2010;28:1963–1972. doi: 10.1200/JCO.2009.26.3541. - DOI - PubMed

LinkOut - more resources